VERA ▲ +2.7% - Vera Therapeutics, Inc. $VERA - Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy Vera Therapeutics shares rose 2.7% following the company's announcement that TRUTAKNA met its primary efficacy endpoints in the ORIGIN 3 trial, demonstrating the drug stabilized eGFR and prevented kidney disease progression through two years in patients with IgA nephropathy. The positive final analysis from the late-stage study supports the therapeutic potential of the company's lead candidate in a serious kidney disease indication. 15-SEP-2026 06:30 AM ET